• A post-approval study of brexu-cel evaluated the outcomes of 76 adult patients with relapsed and refractory B-ALL across 13

• In early-stage, low-risk cervical cancer, the pelvic recurrence rate at 3 years was comparable between radical and routine hysterectomy.